Company news
Alvotech news in 2024
Alvotech's news releases, calls and decks from 2024, newest first.
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
December 22, 2024
Alvotech Reports Financial Results for the First Nine Months of 2024
November 12, 2024
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
November 6, 2024
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
November 3, 2024
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8: 00 am ET
October 29, 2024
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
October 24, 2024
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
October 21, 2024
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
October 9, 2024
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
September 24, 2024
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 25, 2024
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 14, 2024
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
August 14, 2024
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8: 00 am ET
July 31, 2024
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
July 21, 2024
Alvotech Announces Closing of Private Debt Financing
July 10, 2024
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 1, 2024
Alvotech Issues New Shares to Holders of Convertible Bonds
June 30, 2024
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
June 30, 2024
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 25, 2024
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 17, 2024
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
June 10, 2024
Alvotech and STADA add to strategic alliance through denosumab partnership
June 10, 2024
Alvotech Announces Strategic Refinancing Agreement
June 6, 2024
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 28, 2024
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 20, 2024
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 20, 2024
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 20, 2024
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 19, 2024
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 19, 2024
Alvotech S.A. Annual General Meeting to be held June 7, 2024
May 14, 2024
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8: 00 am EDT (12 noon GMT)
May 12, 2024
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 1, 2024
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 29, 2024
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 23, 2024
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 18, 2024
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 15, 2024
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 15, 2024
Alvotech Hosts Audio Call for Investors at 8: 15 am EDT on April 3, 2024
April 2, 2024
Alvotech Announces Increase in Number of Own Shares
March 21, 2024
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 19, 2024
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8: 00 am ET
March 4, 2024
Alvotech Appoints Interim Chief Quality Officer
February 28, 2024
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 25, 2024
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 22, 2024
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
February 14, 2024
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 28, 2024
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 18, 2024
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 2, 2024